(Q59647333)

English

A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study

scientific article published on 01 November 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

phase II clinical trial

1 reference

based on heuristic

inferred from title

0 references

Benny Chung-Ying Zee

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

author name string

R G Tozer

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

S Burdette-Radoux

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

K Berlanger

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

M L Davis

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

R C Lohmann

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

J R Rusthoven

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

N Wainman

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

L Seymour

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

National Cancer Institute of Canada Clinical Trials Group

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

publication date

1 November 2002

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

Investigational New Drugs

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

407-412

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12448658%20AND%20SRC:MED&resulttype=core&format=json

15 December 2019

https://scigraph.springernature.com/pub.10.1023/a:1020694425356

0 references

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of bryostatin 1 in metastatic malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of T-cells by bryostatins: induction of the IL-2 receptor gene transcription and down-modulation of surface receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bryostatin 1 acts synergistically with interleukin-1 alpha to induce secretion of G-CSF and other cytokines from marrow stromal cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of murine melanoma with bryostatin 1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the antitumor activity of bryostatins 1, 5, and 8

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of human T lymphocytes by bryostatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Application of a new multinomial phase II stopping rule using response and early progression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12448658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q59647333&oldid=2099773494"